Daniel O'Day

CymaBay board pushed for 50 cent top up to Gilead's $32.50 offer

Gilead placed its “best and final” offer to buy CymaBay on January 30: $32.50 per share in cash. But the biotech’s board wanted exactly 50 cents more.

Annalee Armstrong Feb 26, 2024 10:49am

Gilead hits go on a host of Arcus cancer programs

Nov 18, 2021 8:00am

Gilead poaches Amgen exec Flavius Martin to run its R&D

Mar 26, 2021 9:40am

Gilead nabs $300M option to buy cancer I-O biotech Tizona

Jul 21, 2020 9:20am

Gilead CEO: Remdesivir could become benchmark for COVID-19 R&D

Apr 30, 2020 7:13pm

How do you get acquired by Gilead? Forty Seven explains

Mar 12, 2020 8:25am